Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Forbush Decrease Catalog at MESSENGER by Emma Davies (12046748)

Beverage Containing Dispersible Yeast β-Glucan Decreases Cold/Flu Symptomatic Days After Intense Exercise: A Randomized Controlled Trial by Eunice Mah (5918042)

“…Total URTI severity was significantly lower for β-glucan (4.52 ± 1.61) compared to control (5.60 ± 2.23). Specifically, lower (<i>p</i> < .05) severity ratings for nasal discharge and sore throat were reported for β-glucan compared to control. …”

Glucose depletion decreases SBPM. by David S. Tourigny (7224299)

“…Replenishment of glucose alone is sufficient to restore a significantly higher SBPM. No substrate 20min <i>versus</i> glucose and pyruvate P = 0.013; no substrate 20min <i>versus</i> no substrate 10min P = 0.003; glucose alone <i>versus</i> no substrate 20min P = 0.012; N = 4. …”

Decrease in the number of intestinal pDCs in <i>Enpp3</i>^<i>-/-</i> mice. by Yoki Furuta (3772735)

Effect of i.c.v. infusion of rrIL-1ra on poly I:C-induced decrease in spontaneous activity. by Masanori Yamato (534076)

Sepsis decreases the frequencies of CD4 T cells. by Mian Zhou (339595)

<i>shk-1</i> mutants display decreased glycogen storage. by Longjun Pu (20685717)

Nivalenol (NIV) decreases chondrocyte viability in a dose and duration-dependent manner. by Siyuan Li (178640)

Overexpression of Jagn1 decreases steady-state insulin levels. by Courtney Nosak (1807867)

Relationship between N-status (N:C) and <i>T</i>_<i>max</i> for cells of different size. by Kevin J. Flynn (2615002)

Rapamycin decreases phosphorylation of S6. by Adam L. Hartman (308128)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

“…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”

DataSheet_1_microRNA-155 Is Decreased During Atherosclerosis Regression and Is Increased in Urinary Extracellular Vesicles During Atherosclerosis Progression.docx by Stephen Fitzsimons (9856793)

“…Surface marker expression and miR content were analyzed in urinary extracellular vesicles (uEVs) obtained from patients diagnosed with unstable (n = 12) and stable (n = 12) CAD.</p>Results<p>Here, we report that the 1% cholesterol diet increased miR-155 expression while CLA blend supplementation decreased miR-155 expression in the aorta during atherosclerosis regression in vivo. …”

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

AIQ decreases CIA severity. by Elena Gonzalez-Rey (35541)

Position of the residues on the surface of (H1N1) A/PR/8/34 influenza hemagglutinin trimer decreasing the binding of PN-SIA28. by Nicola Clementi (174058)

Virion production is significantly decreased by rapamycin treatment. by Lisa A. Nichols (357612)

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)